Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
复制标题
DOI：
10.1016/j.euroneuro.2004.07.003
复制
发表时间：
2005-01-01
影响因子：
5.6
通讯作者：
David, AS
中科院分区：
文献类型：
--
作者：
Chue, P;Eerdekens, M;David, AS
对640例精神分裂症患者进行了长效注射用利培酮与口服利培酮片的双盲对照研究。所有患者均接受1-6 mg口服利培酮8周的灵活剂量。第5-8周期间剂量稳定。在第8周结束时，病情稳定的患者被随机分配接受长效利培酮（活性注射，模拟口服）或继续口服利培酮（模拟注射，活性口服）12周。阳性和阴性症状量表（PANSS）总分从基线到终点有显著改善（P
A double-blind study of long-acting injectable risperidone and oral risperidone tablets was conducted in 640 patients with schizophrenia. All patients received flexible doses of 1-6 mg of oral risperidone for 8 weeks. Doses were stable during weeks 5-8. At the end of week 8, symptomatically stable patients were randomly assigned to receive long-acting risperidone (active injections, dummy oral) or continued oral risperidone (dummy injections, active oral) for 12 weeks. Significant improvements were demonstrated from baseline to endpoint in Positive and Negative Syndrome Scale (PANSS) total (P